SEC Filing Summary: Spherix Incorporated (10-Q)
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for Spherix Incorporated for the period ended March 31, 2010. The company operates two segments: Biospherics, which is developing D-tagatose as a potential treatment for Type 2 diabetes, and Health Sciences, which provides technical and regulatory consulting services. The company is a smaller reporting company and is not a shell company.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Revenue | $332,291 | $360,670 |
| Net Loss | $(2,147,876) | $(2,066,084) |
| Net Loss Per Share (Basic/Diluted) | $(0.13) | $(0.14) |
| Cash and Cash Equivalents | $6,263,047 | $7,778,180 (End of Q1 2009) |
| Working Capital | $5.5 million | $7.7 million (Dec 31, 2009) |
| Net Cash Used in Operating Activities | $(2,762,955) | $(1,491,745) |
| Total Assets | $7,359,021 | $10,155,308 (Dec 31, 2009) |
| Total Liabilities | $2,230,876 | $2,883,432 (Dec 31, 2009) |
Material Changes vs. Prior Period
- Revenue: Decreased by approximately 8% to $332,291, driven entirely by the Health Sciences segment. The Biospherics segment generated no revenue.
- Operating Expenses: Total operating expenses increased slightly to $2,482,155. While Research and Development (R&D) expenses decreased by roughly 16% (due to reduced costs in India compared to the prior year), Selling, General, and Administrative (SG&A) expenses increased significantly by 38% to $1,050,647 due to expanded commercialization efforts.
- Liquidity: Cash and cash equivalents decreased by approximately $2.76 million during the quarter. Working capital declined from $7.7 million at year-end 2009 to $5.5 million.
- Interest Income: Decreased to $1,988 from $24,447 in the prior year due to lower market rates and reduced funds available for investment.
Guidance, Outlook, and Risks
- Clinical Trials: The company is conducting Phase 2 and Phase 3 trials for D-tagatose. The efficacy portion of the Phase 3 trial and the Phase 2 Dose Range trial are expected to complete in mid-to-late 2010. The safety portion of the Phase 3 trial is expected in early 2011.
- Capital Needs: Management expects to need between $8 million and $11 million over the next 12 months to complete trials and fund commercialization. The company intends to delay raising funds until after Phase 3 efficacy results are announced.
- Fundraising Constraints: Due to SEC rules regarding Form S-3 registration statements, the company may be unable to conduct a registered direct primary offering until mid-November 2010. Any offering before then would likely require a Form S-1, which is more time-consuming. Additionally, NASDAQ rules may require stockholder approval for issuances exceeding 20% of outstanding stock.
- Regulatory Risks: The FDA regulatory climate has changed, potentially requiring additional studies (e.g., cardiovascular risks) before an NDA submission. Management is consulting with experts to determine necessary steps.
Investor Verification Checklist
- Verify the timeline and enrollment status of the Phase 2 and Phase 3 clinical trials for D-tagatose.
- Confirm the company's ability to raise the required $8–$11 million in capital before cash reserves are depleted.
- Review the specific requirements from FDA advisors regarding potential additional studies needed for NDA submission.
- Monitor the status of the Form S-1 registration statement if fundraising is required before November 2010.
- Assess the sustainability of the Health Sciences consulting revenue stream given the economic environment.